Capdevila, J., Hernando, J., Molina-Cerillo, J., Serrahima, M. P., Sanz, M. T., Castelo, B., Álvarez-Escolá, C., Carmona-Bayonas, A., Navarro, I. B., Iglesias, L., Bover, M., Garcia-Alvarez, A., Lavernia, J., Tur, R. Y., Ruiz, S., Baste, N., Lorenzo-Lorenzo, I., Sanchez-Hernandez, A., Sanz-Garcia, E., Marquina, G., Nuciforo, P., Elguero, B., Grande, E., Alonso-Gordoa, T. (2026). Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial. Nature Communications. https://doi.org/10.1038/s41467-026-71155-y